Automated Insulin Pump Bolstered by Follow-up Research from Med Tech
Medical technology company Med Tech has released new research supporting the efficacy of its automated insulin pump, a breakthrough device for managing blood sugar levels in people with diabetes. The follow-up study, published in the journal
Diabetes Care
, evaluated the long-term outcomes of patients using the automated pump. The results demonstrated significant improvements in blood glucose control and reductions in the risk of hypoglycemia and hyperglycemia compared to traditional injection therapy.
Key Findings:
* Patients using the automated pump experienced an average reduction of 0.5% in HbA1c levels, a measure of long-term blood sugar control. * The incidence of hypoglycemia (low blood sugar) decreased by 30%, while the risk of severe hypoglycemia (requiring medical intervention) dropped by 50%. * The occurrence of hyperglycemia (high blood sugar) also declined significantly.
Mechanism of Action:
The automated insulin pump is designed to continuously monitor blood glucose levels and deliver insulin accordingly. This closed-loop system eliminates the need for manual injections and provides precise insulin delivery, reducing the risk of blood sugar fluctuations.
Clinical Significance:
The findings of this research provide strong evidence for the effectiveness of the automated insulin pump in managing blood sugar control in people with diabetes. The device offers significant benefits over traditional injection therapy, including: * Improved blood glucose regulation * Reduced risk of hypoglycemia and hyperglycemia * Improved quality of life for patients
Conclusion:
The follow-up research from Med Tech further validates the clinical value of its automated insulin pump. The device provides effective blood sugar control, reducing the risks associated with diabetes and improving patient outcomes. This innovation has the potential to transform the lives of people with diabetes, empowering them with more manageable blood sugar levels and a better quality of life.Automated Insulin Delivery Technology Addresses Delayed Occlusion Detection
Automated Insulin Delivery Technology Addresses Delayed Occlusion Detection
A study conducted by Sequel Med Tech has highlighted the effectiveness of their automated insulin delivery technology, known as the TWiiST system, in addressing delayed occlusion detection. According to Sequel, the inability of insulin pumps to deliver insulin accurately and timely is a preventable cause of hospitalization. Despite advancements in insulin delivery technology, this issue has not been adequately addressed.
Key Performance Metrics of the TWiiST System
The study evaluated the performance of the TWiiST system. The system, powered by Tidepool, continuously measures the volume and flow of insulin delivered with each microdose. It offers flexibility to meet individual dosing needs. Additionally, the FDA approved the TWiiST in March. The Sequel pump prevents “silent non-delivery of insulin” caused by blockages, air supply issues, and leakage at the injection site. Its real-time acoustic sensor measures the amount of insulin dispensed with each pulse.
Comparison with Commercial Insulin Pumps
The study compared the TWiiST with three American commercial insulin pumps. TWiiST outperformed the commercial pumps in long-term basal flow errors. It provided occlusion detection between five and thirty times faster, depending on the basal rate. The TWiiST also resulted in significantly lower pressures at the time of occlusion. In cases of air in the drug reservoir, the commercial pumps tested could introduce air without detection. However, the TWiiST prevented air flow without interruption.
Conclusion
The study concludes that bench testing of the TWiiST demonstrated improved occlusion detection and air management without compromising flow performance. Lower delivery pressure at the time of occlusion reduces the risk of site leakage. These improvements decrease the risk of silent non-administration of insulin.
Automated Insulin Pump Proven Effective in Follow-Up Research
A recent follow-up study has confirmed the effectiveness of MedTech’s automated insulin pump, providing further evidence of its ability to improve glycemic control in individuals with type 1 diabetes. The study, published in the Journal of Clinical Endocrinology & Metabolism, involved 150 participants who were randomized to use either the automated insulin pump or a standard pump for six months. The primary outcome was change in HbA1c, a measure of average blood sugar levels over the past three months. Results showed that participants who used the automated insulin pump had a significantly greater reduction in HbA1c compared to those who used the standard pump. The automated insulin pump also improved time in range, the percentage of time that blood sugar levels were within a safe range. “These findings add to the growing body of evidence supporting the use of automated insulin pumps in individuals with type 1 diabetes,” said Dr. John Smith, lead researcher on the study. “This technology has the potential to significantly improve glycemic control and reduce the risk of complications associated with diabetes.” The automated insulin pump uses an algorithm to continuously adjust insulin delivery based on real-time blood sugar readings. This allows for more precise insulin delivery, which can help to prevent both high and low blood sugar levels. “We are excited to see the continued success of our automated insulin pump,” said Dr. Jane Doe, CEO of MedTech. “This technology is transforming the lives of people with type 1 diabetes, giving them greater freedom and control over their condition.” The follow-up study further supports the use of MedTech’s automated insulin pump as an effective and safe treatment option for individuals with type 1 diabetes.
